Significance of Temporal Muscle Thickness in Chronic Subdural Hematoma.
chronic subdural hematoma
outcome
recurrence
risk factors
sarcopenia
temporal muscle thickness
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Oct 2022
31 Oct 2022
Historique:
received:
21
10
2022
revised:
29
10
2022
accepted:
30
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Background: Reduced temporal muscle thickness (TMT) was verified as an independent negative prognostic parameter for outcome in brain tumor patients. Independent thereof, chronic subdural hematoma (CSDH) is a neurosurgical condition with high recurrence rates and unreliable risk models for poor outcome. Since sarcopenia was associated with poor outcome, we investigated the possible role of TMT and the clinical course of CSDH patients. Methods: This investigation is a single-center retrospective study on patients with CSDH. We analyzed the radiological and clinical data sets of 171 patients with surgically treated CSDH at a University Hospital from 2017 to 2020. Results: Our analysis showed a significant association between low-volume TMT and increased hematoma volume (p < 0.001), poor outcome at discharge (p < 0.001), and reduced performance status at 3 months (p < 0.002). Conclusion: TMT may represent an objective prognostic parameter and assist the identification of vulnerable CSDH patients.
Identifiants
pubmed: 36362682
pii: jcm11216456
doi: 10.3390/jcm11216456
pmc: PMC9654786
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Physiol. 2017 Dec 12;8:1045
pubmed: 29311975
J Neurosurg Sci. 2010 Sep;54(3):99-103
pubmed: 21423076
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Sci Rep. 2021 Oct 5;11(1):19717
pubmed: 34611230
JAMA Surg. 2019 Aug 1;154(8):716-723
pubmed: 31066880
World Neurosurg. 2017 Jan;97:532-537
pubmed: 27777156
Surg Neurol Int. 2021 Apr 14;12:151
pubmed: 33948321
Neurol Sci. 2022 May;43(5):3089-3095
pubmed: 34846582
J Neuroinflammation. 2017 May 30;14(1):108
pubmed: 28558815
PLoS One. 2018 Oct 4;13(10):e0204331
pubmed: 30286106
Nutrients. 2022 Feb 06;14(3):
pubmed: 35277046
Cancer Manag Res. 2021 Aug 24;13:6621-6632
pubmed: 34466032
World Neurosurg. 2020 May;137:e526-e534
pubmed: 32061954
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Surg Neurol Int. 2021 Feb 23;12:67
pubmed: 33767871
Clin Neurol Neurosurg. 2021 Feb;201:106444
pubmed: 33395619
Neurosurg Rev. 2022 Feb;45(1):701-708
pubmed: 34231088
Nutr Neurosci. 2022 Aug;25(8):1756-1763
pubmed: 33666524
Neuro Oncol. 2019 Dec 17;21(12):1587-1594
pubmed: 31369680
Acta Neurochir (Wien). 2018 Apr;160(4):761-766
pubmed: 29455413
World Neurosurg. 2020 Sep;141:339-345
pubmed: 32593768
J Neurooncol. 2018 Oct;140(1):173-178
pubmed: 30008154
J Trauma Acute Care Surg. 2021 Dec 1;91(6):e134-e141
pubmed: 34538825
Clin Cancer Res. 2022 Jan 1;28(1):129-136
pubmed: 34667022
Clin Med (Lond). 2016 Oct;16(5):455-458
pubmed: 27697810
Crit Care Med. 2015 May;43(5):1102-11
pubmed: 25574794
Neurosurg Rev. 2021 Apr;44(2):961-970
pubmed: 32112162
Age (Dordr). 2013 Dec;35(6):2377-88
pubmed: 23456136